Company Overview

DexCom, Inc. is a leading medical device company headquartered in San Diego, California, specializing in the design, development, and commercialization of continuous glucose monitoring (CGM) systems. Incorporated in 1999, Dexcom has been a pioneer in glucose biosensing technology for over 25 years, setting industry standards in diabetes management.

The company's shares are publicly traded on the Nasdaq stock exchange under the ticker symbol DXCM. DexCom holds a significant market presence, with its market capitalization reaching approximately $30.02 billion as of September 17, 2025.

Business Model & Products

DexCom operates on a robust business model that combines the sale of advanced medical devices with recurring revenue streams from consumables and sensor replacements. This model is designed to support the ongoing needs of patients, caregivers, and clinicians in managing diabetes and metabolic health.

Core Product Portfolio

The company offers a range of integrated CGM systems and related services:

- Dexcom G6 and Dexcom G7: Advanced integrated CGM systems designed for comprehensive diabetes management.

- Dexcom Share: A remote monitoring system enabling users to share their glucose data with designated individuals.

- Dexcom Real-Time API: Allows third-party developers to integrate real-time CGM data into their digital health applications and devices.

- Dexcom ONE: A system developed to serve as a replacement for traditional finger stick blood glucose testing for diabetes treatment decisions.

- Stelo: An over-the-counter glucose biosensor targeted at adults with prediabetes and Type 2 diabetes who are not on insulin therapy.

These flagship products provide significant advantages over conventional blood glucose monitoring methods by continuously tracking glucose levels, offering a less intrusive and more dynamic approach to health monitoring.

Financial Performance and Market Position

DexCom has demonstrated strong financial growth and impressive revenue expansion over recent periods.

Key Financial Metrics (as of September 2025):

- Market Capitalization: $30.02 Billion (as of September 17, 2025)

- TTM Revenue: $4.30 Billion USD (as of September 2025)

- Annual Revenue (2024): $4.03 Billion USD

- Annual Revenue (2023): $3.62 Billion USD

Quarterly Performance Highlights:

- Q2 2025: Revenue grew 15% year-over-year to $1.157 billion.

- Q1 2025: Revenue grew 12% year-over-year to $1.036 billion.

- Q4 2024: Revenue grew 8% year-over-year to $1.114 billion.

The company achieved a GAAP operating income of $212.6 million in Q2 2025, representing 18.4% of revenue, indicating strong operational efficiency alongside revenue growth.

Strategic Partnerships & Distribution

DexCom collaborates with key partners to advance its technology and expand its reach. A notable collaboration is with Verily Life Sciences LLC and Verily Ireland Limited, focusing on the development of blood-based or interstitial glucose monitoring products. The company employs a direct sales strategy, marketing its products to endocrinologists, physicians, and diabetes educators.

Innovation & Market Expansion

DexCom continuously expands its market presence through innovative product development and successful regulatory approvals. Key achievements include:

- FDA clearance for the Dexcom G7 15 Day CGM System.

- Launch of AI-based Smart Food Logging features.

- Enhancement of the Stelo customer experience.

The introduction of Stelo as the first over-the-counter glucose biosensor in the U.S. (launched Q3 2024) has significantly expanded accessibility for individuals managing prediabetes and Type 2 diabetes.

Financial Strength & Future Outlook

DexCom maintains a strong balance sheet, bolstering its capacity for continued growth and innovation. The company holds approximately $2.93 billion in cash, cash equivalents, and marketable securities, supporting its expansion initiatives.

For fiscal year 2025, DexCom has raised its revenue guidance to $4.600 - $4.625 billion (representing 14-15% growth), while maintaining guidance for other key metrics, including a Non-GAAP Operating Margin of approximately 21%.

Leadership Transition

The company has announced a CEO succession plan: Jake Leach is set to become CEO effective January 1, 2026, with current CEO Kevin Sayer transitioning to the role of Executive Chairman.

DexCom's commitment to empowering individuals to manage their health through innovative biosensing technology solidifies its market leadership in the rapidly expanding diabetes management sector. The company's strategic focus on innovation, key partnerships, and global expansion positions it for sustained growth within the dynamic CGM market.